What's Going On With Bristol Myers Squibb Stock On Monday?

Core Insights - Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) has shown significant efficacy in treating relapsed or refractory indolent B-cell non-Hodgkin lymphoma, meeting both primary and key secondary endpoints in the Phase 2 TRANSCEND FL trial [1][2] - The FDA has approved Breyanzi for multiple subtypes of non-Hodgkin lymphoma, making it the CAR T cell therapy with the broadest treatment indications for B-cell malignancies [3] - Breyanzi's sales are projected to exceed $747 million in 2024, reflecting a more than 100$6.4 billion lawsuit against Bristol Myers Squibb was dismissed due to the plaintiff's lack of standing, which could have implications for the company's legal and financial stability [4] Market Performance - Bristol Myers Squibb's stock price decreased by 2.87%, closing at $55.22 [5]